Market Overview

UPDATE: Piper Jaffray Initiates Coverage On Lion Biotechnologies Based On DCF Analysis


In a report published Monday, Piper Jaffray analyst Joshua E. Schimmer initiated coverage on Lion Biotechnologies Inc (NASDAQ: LBIO) with an Overweight rating and $21.00 price target.

In the report, Piper Jaffray noted, "We are initiating coverage on LBIO with an OW rating and $21 PT based on our DCF analysis. The company has a license from the NIH to develop TILs (tumor infiltrating lymphocytes) to treat melanoma as well as other solid tumors likely to be responsive to this approach. Unlike some emerging cellular therapy platforms, TILs have a unique advantage in being able to target a repertoire of individualized tumor antigens. With highly promising results already reported in melanoma, we believe LBIO's platform will play a very important role in the evolving cancer immunotherapy space."

Lion Biotechnologies closed on Friday at $9.00.

Latest Ratings for LBIO

Mar 2017Wells FargoInitiates Coverage OnOutperform
Apr 2015Chardan CapitalInitiates Coverage onBuy
Apr 2015FBR CapitalInitiates Coverage onOutperform

View More Analyst Ratings for LBIO
View the Latest Analyst Ratings


Related Articles (LBIO)

View Comments and Join the Discussion!

Posted-In: Joshua E. Schimmer Piper JaffrayAnalyst Color Initiation Analyst Ratings

Latest Ratings

PMTB of A SecuritiesMaintains18.5
IVRB of A SecuritiesMaintains3.0
EFCB of A SecuritiesMaintains15.5
NYMTB of A SecuritiesMaintains3.5
NLYB of A SecuritiesMaintains8.5
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at